RootK KRX:195990KOSDAQ

에이비프로바이오 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked1since Sep 11

In Q3 2026, RootK reported revenue of ₩10.3bn, up 30.8% year on year, and an operating loss of ₩1.8bn. RootK (에이비프로바이오) appeared in 0 Korean news articles and 1 DART filing over the past seven days.

Filing signals 4 quarters of losses Screener

RootK today: up or down?

No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.

Upcoming dates as filed

  • Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026

Dates RootK stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.

RootK quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q3 2026₩10.3bn+30.8%−₩1.8bn
margin −17.4%
−₩3.2bn
Q2 2026₩9.0bn-1.1%−₩4.1bn
margin −45.6%
−₩5.8bn
Q1 2026₩7.9bn-11.1%−₩2.3bn
margin −28.7%
₩2.1bn
Q4 2025 derived₩6.1bn-41.3%−₩1.8bn
margin −29.6%
−₩1.1bn
Q3 2025₩7.9bn-40.7%−₩1.7bn
margin −21.6%
−₩206m
Q2 2025₩9.1bn+365.6%−₩2.5bn
margin −27.7%
−₩44.4bn
Q1 2025₩8.9bn+45.3%−₩3.3bn
margin −36.8%
−₩3.3bn
Q4 2024 derived₩10.3bn+69.9%−₩3.5bn
margin −34.0%
−₩22.2bn

RootK ranks #1930 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

RootK top stories 2 weeks, by number of outlets

No story covered by multiple outlets in the past two weeks.

Latest RootK news Korean headlines